The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma ... or refractory extensive-stage small-cell lung cancer (SCLC), with the ...

Besides osteosarcoma, GSK is also developing GSK’227 for treating extensive-stage small-cell lung cancer (ES-SCLC), an aggressive and difficult-to-treat cancer. Last month, the European ...

GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated ...